Healthcare Equipment and Supplies
Company Overview of EndoGastric Solutions, Inc.
EndoGastric Solutions, Inc., a medical device company, develops, markets, and sells natural orifice surgical products and procedures to advance the treatment of gastrointestinal diseases. It offers EsophyX, a technology that enables transoral reconstructive surgery; SerosaFuse Fasteners, a non-resorbable polypropylene material product that have equivalent web strength to a 3.0 suture; trainer-led courses for surgeons; and consultative, support, pre-authorization, internal appeal, and external medical review services. The company was formerly known as EsophyX, Inc. and changed its name to EndoGastric Solutions, Inc. in 2005. EndoGastric Solutions, Inc. was founded in 2002 and is headquartered...
1900 O'Farrell Street
San Mateo, CA 94403
Founded in 2002
Key Executives for EndoGastric Solutions, Inc.
Chief Executive Officer, President and Director
Director of Finance and Controller
Senior Director of US Sales
Compensation as of Fiscal Year 2016.
EndoGastric Solutions, Inc. Key Developments
FDA Clears EndoGastric Solutions’ EsophyX® Device
May 12 16
EndoGastric Solutions announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the EsophyX® Z device. Designed for compatibility with the company’s existing 7.5 mm SerosaFuse® Implantable Fastener cartridges, EsophyX Z allows physicians to reconstruct the gastroesophageal valve and then secure tissue with a trigger-like handle, making the device similar to stapler like devices often utilized in surgery. EsophyX Z will enter a limited release in the U.S. before full commercialization during the summer. Additionally, it is being used in the American Gastroenterological Association’s STAR Registry, which will provide the first real-world data comparing patient outcomes after traditional laparoscopic surgery and TIF with the EsophyX® device.
EndoGastric Solutions Announces Presentation of Three-Year Follow-Up Data from TEMPO
Mar 17 16
EndoGastric Solutions announced the presentation of three-year follow-up data from TEMPO, a prospective, randomized, multicenter clinical study. The data confirms long-term control of chronic GERD after a Transoral Incisionless Fundoplication (TIF®) procedure with the EsophyX® device. The study will be presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2016 Annual meeting, taking place from March 16-19, 2016 in Boston, Massachusetts. Sixty-three patients who suffered from troublesome chronic GERD symptoms were randomized to either undergo the TIF procedure (n=40) using the EsophyX device or take proton pump inhibitor (PPI) therapy (n=23); all patients in PPI control group crossed over and received TIF procedures six months after the start of the study. At up to 36 months follow-up, 91% of patients reported elimination of troublesome regurgitation, 70% were able to completely stop PPI therapy, and reflux esophagitis healed in 87% of patients. The data will be presented the SS08 Flexible Endoscopy session starting at 3:30 PM to 5:30 PM on March 17, 2016 in Ballroom A moderated by Frederick L. Greene, MD and G. V. Rao, MS, MAMS.
EndoGastric Solutions Secures $50 Million in Financing
Dec 1 15
EndoGastric Solutions announced that it has secured additional new financing of up to $50.0 million, led by CRG (formerly Capital Royalty L.P.) and existing EGS investors including Advanced Technology Ventures, Canaan Partners, Chicago Growth Partners, Foundation Medical Partners, and Radius Ventures. EGS plans to use proceeds from the financing to begin broad-scale commercialization, as well as making further R&D investments in next generation products used in their TIF procedure.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|